Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy

Factor XIa inhibitor moving into Phase 2 Trials for Secondary Stroke Prevention Bristol-Myers Squibb to receive upfront payment and companies to share development and commercialization costs, and global profits  

• Source: news.bms
• 607
• April 23, 2018